Back to search
FDAFDA · Food and drugs·Recall number D-0224-2025

Irbesartan Tablets USP, 300 mg, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE, Pulaski, TN 38478. NDC 50268-442-15

Published February 19, 2025 · Recall initiated: January 21, 2025

Summary

FDA records drug Class II recall D-0224-2025, published February 19, 2025 and initiated January 21, 2025. Recalling firm: AvKARE; Status: Ongoing; Reported quantity: 341 cartons; Lot: Lot 45279, Exp 03/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Out of Specification for Dissolution

What to do

Voluntary: Firm initiated · Letter

Get an email if IRBESARTAN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
IRBESARTAN
Manufacturer
AvKARE
Distributor
Nationwide in the USA
Lot
Lot 45279, Exp 03/31/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Irbesartan Tablets USP, 300 mg, 50 Tablets (5 x 10) Unit Dose per carton, Manufactured for: AvKARE, Pulaski, TN 38478. NDC 50268-442-15 recalled?

Yes. FDA published recall D-0224-2025 on February 19, 2025. Reported hazard: Out of Specification for Dissolution

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: IRBESARTAN.